Cargando…

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

Detalles Bibliográficos
Autores principales:	McCurdy, Arleigh, Mian, Hira, LeBlanc, Richard, Jimenez-Zepeda, Victor H., Su, Jiandong, Masih-Khan, Esther, Visram, Alissa, Louzada, Martha, Song, Kevin, White, Darrell, Sebag, Michael, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Bergstrom, Debra, Kotb, Rami, Kaedbey, Rayan, Gul, Engin, Reece, Donna, Venner, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460788/ https://www.ncbi.nlm.nih.gov/pubmed/37635183 http://dx.doi.org/10.1038/s41408-023-00888-6

Ejemplares similares

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
por: Côté, Julie, et al.
Publicado: (2023)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
por: Mian, Hira, et al.
Publicado: (2022)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
por: Cherniawsky, Hannah M., et al.
Publicado: (2020)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences
por: Pritlove, Cheryl, et al.
Publicado: (2021)

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
por: Figueiredo, Amarilis, et al.
Publicado: (2019)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Sterrett, Russell, et al.
Publicado: (2021)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
por: Mian, Hira, et al.
Publicado: (2023)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
por: Kis, Olena, et al.
Publicado: (2017)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
por: Tessier, Camille, et al.
Publicado: (2021)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

Vertebral compression fractures in multiple myeloma: redefining the priorities during the COVID-19 pandemic
por: Giorgi, P. D., et al.
Publicado: (2020)

Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report
por: Alabdulbaqi, Manar, et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
por: Alfarra, Helmi, et al.
Publicado: (2020)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

TAZ upregulates MIR‐224 to inhibit oxidative stress response in multiple myeloma
por: Abegunde, Samuel O., et al.
Publicado: (2023)

Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma
por: Chen, Yuxi, et al.
Publicado: (2018)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

P978: EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS
por: Al-Kaisi, Firas, et al.
Publicado: (2023)

Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
por: Visram, Alissa, et al.
Publicado: (2021)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
por: Reece, Donna, et al.
Publicado: (2012)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2b66rhmu6k481e3qc0vuaum6fk